Pulmocide key facts
as of Oct 2026- Developer of antifungal drugs designed to treat acute and chronic respiratory diseases.
- Pulmocide is valued at approximately $291.6M as of Oct 2026 (last reported valuation).
- It has raised $267.6M; the latest was Later Stage VC ($28.0M) in Sep 2025.
- Notable investors include F-Prime Capital, Eight Roads, Johnson & Johnson JJDC, SV Health Investors, SR One Capital Management — 15 tracked in total.
- Status: Privately Held (backing).
Pulmocide's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Pulmocide: the Monday email on marks, rounds and moves
Pulmocide funding rounds
No funding rounds for Pulmocide are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Pulmocide
15+Pulmocide valuation
Pulmocide's last reported valuation was $292 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Pulmocide investors
15 investors are on record for Pulmocide, including F-Prime Capital, Eight Roads, Johnson & Johnson JJDC and SV Health Investors. By type, the record holds 4 venture capital firms and 2 asset managers.
About Pulmocide
Developer of antifungal drugs designed to treat acute and chronic respiratory diseases. The company's drugs are specifically designed for inhaled use to maximize the amount of medicine in the lung and spare systemic exposure and are expected to provide superior efficacy against respiratory aspergillosis while minimizing systemic toxicities, optimized for lung delivery and minimal systemic absorption, enabling doctors to provide a safe and effective treatment for their patients
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2007
- Employees
- 28
- Website
- pulmocide.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.